Key result
Transcatheter closure of atrial septal defects and patent foramen ovale using FDA-approved devices is safe and effective, offering high closure rates and shorter hospital stays compared to surgery.
Why the study?
Does transcatheter closure of ASD or PFO using FDA-approved devices improve closure rates and reduce recurrent stroke compared to medical therapy or surgery?
Design
Review
Authors
Loading...
Transcatheter ASD closure yields shorter stays and fewer complications than surgery; reinforces consensus on device safety and efficacy in suitable patients.
Does transcatheter closure of ASD or PFO using FDA-approved devices improve closure rates and reduce recurrent stroke compared to medical therapy or surgery?
Transcatheter closure of ASD and PFO using FDA-approved devices is a safe and effective alternative to surgery and medical therapy, providing high closure rates and reducing recurrent stroke risk.
Shrivastava et al. (2023) conducted a review in Atrial Septal Defect (ASD) and Patent Foramen Ovale (PFO). Transcatheter ASD/PFO closure devices vs. Medical therapy or surgical closure was evaluated. Transcatheter closure of atrial septal defects and patent foramen ovale using FDA-approved devices is safe and effective, offering high closure rates and shorter hospital stays compared to surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: